^
    Back
    Association details:
    Biomarker:ROS1 fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Anluoqing (envonalkib) (ALK inhibitor, ROS1 inhibitor, c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Eur J Cancer
    Title:

    First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements

    Published date:
    08/05/2022
    Excerpt:
    For TKI-treated patients, the ORR was 37.5% (6/16), and the mPFS was 5.4 months (95%CI 3.6-9.1). The ORR was 66.7% (2/3) in patients with ROS1 fusion at dose level ≥200 mg BID….TQ-B3139 was well-tolerated and exhibited promising anti-tumor activities in patients with ALK and ROS1 positive advanced NSCLC.
    DOI:
    10.1016/j.ejca.2022.06.037
    Trial ID:
    NCT03099330